Cargando…

Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance

Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ireland, Lucy V., Mielgo, Ainhoa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189297/
https://www.ncbi.nlm.nih.gov/pubmed/30356656
http://dx.doi.org/10.3389/fcell.2018.00131
_version_ 1783363337749266432
author Ireland, Lucy V.
Mielgo, Ainhoa
author_facet Ireland, Lucy V.
Mielgo, Ainhoa
author_sort Ireland, Lucy V.
collection PubMed
description Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also known as stromal cells, which include fibroblasts, immune cells, and cells from the vasculature. Therapies targeting cancer cells have shown limited effectiveness in tumors characterized by a rich tumor stroma. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant non-cancerous cells in the tumor stroma and have emerged as key players in cancer progression, metastasis and resistance to therapies. This review describes the recent advances in our understanding of how CAFs and TAMs confer chemoresistance to tumor cells and discusses the therapeutic opportunities of combining anti-tumor with anti-stromal therapies. The continued elucidation of the mechanisms by which TAMs and CAFs mediate resistance to therapies will allow the development of improved combination treatments for cancer patients.
format Online
Article
Text
id pubmed-6189297
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61892972018-10-23 Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance Ireland, Lucy V. Mielgo, Ainhoa Front Cell Dev Biol Physiology Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also known as stromal cells, which include fibroblasts, immune cells, and cells from the vasculature. Therapies targeting cancer cells have shown limited effectiveness in tumors characterized by a rich tumor stroma. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant non-cancerous cells in the tumor stroma and have emerged as key players in cancer progression, metastasis and resistance to therapies. This review describes the recent advances in our understanding of how CAFs and TAMs confer chemoresistance to tumor cells and discusses the therapeutic opportunities of combining anti-tumor with anti-stromal therapies. The continued elucidation of the mechanisms by which TAMs and CAFs mediate resistance to therapies will allow the development of improved combination treatments for cancer patients. Frontiers Media S.A. 2018-10-09 /pmc/articles/PMC6189297/ /pubmed/30356656 http://dx.doi.org/10.3389/fcell.2018.00131 Text en Copyright © 2018 Ireland and Mielgo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Ireland, Lucy V.
Mielgo, Ainhoa
Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
title Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
title_full Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
title_fullStr Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
title_full_unstemmed Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
title_short Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
title_sort macrophages and fibroblasts, key players in cancer chemoresistance
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189297/
https://www.ncbi.nlm.nih.gov/pubmed/30356656
http://dx.doi.org/10.3389/fcell.2018.00131
work_keys_str_mv AT irelandlucyv macrophagesandfibroblastskeyplayersincancerchemoresistance
AT mielgoainhoa macrophagesandfibroblastskeyplayersincancerchemoresistance